A Phase I Pilot Study of Immunotherapy Using Lenalidomide Plus 'Bystander' Vaccine in Patients With High-Risk Myelodysplastic Syndrome (MDS).
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 05 Jul 2017
At a glance
- Drugs CD40L GVAX (Primary) ; Lenalidomide (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- 30 Jun 2017 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
- 10 Jun 2017 Biomarkers information updated
- 23 Jan 2017 Planned End Date changed from 1 Mar 2017 to 1 Dec 2017.